Risk factors for breast carcinoma in women with proliferative breast disease

William D. Dupont, Amy C Degnim, Melinda E. Sanders, Jean F. Simpson, Lynn C. Hartmann

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

We review the evidence that proliferative breast disease increases the risk of breast cancer. Results from six cohorts give consistent estimates of these risks. The combined estimate of the relative risk associated with proliferative disease without atypia is 1.65 with a 95% confidence interval (CI) of 1.5 to 1.9. The relative risk of breast cancer associated with atypical hyperplasia is 4.19 (95% CI 3.7-4.7). Estimates of the cumulative absolute risk of invasive breast cancer in the Nashville Breast Cohort and the Mayo Clinic Cohort are also given. These risks are remarkably consistent and average about 25% in the 25 years after a diagnosis of atypical hyperplasia. The chapter also reviews the evidence on how age, a family history of breast cancer, and proliferative breast disease interact to affect breast cancer risk. The risks associated with fibroadenoma and radial scar are also reviewed, as are the effects of time since diagnosis and the risk of hormone replacement therapy in women with a history of proliferative disease.

Original languageEnglish (US)
Title of host publicationThe Breast
Subtitle of host publicationComprehensive Management of Benign and Malignant Diseases
PublisherElsevier Inc.
Pages264-271.e2
ISBN (Print)9780323359559
DOIs
StatePublished - Aug 24 2017

Fingerprint

Breast Diseases
Breast Neoplasms
Hyperplasia
Confidence Intervals
Fibroadenoma
Hormone Replacement Therapy
Cicatrix
Breast

Keywords

  • Atypical hyperplasia
  • Breast neoplasms pathology/prevention and control
  • Breast pathology
  • Proliferative disease without atypia
  • Risk assessment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dupont, W. D., Degnim, A. C., Sanders, M. E., Simpson, J. F., & Hartmann, L. C. (2017). Risk factors for breast carcinoma in women with proliferative breast disease. In The Breast: Comprehensive Management of Benign and Malignant Diseases (pp. 264-271.e2). Elsevier Inc.. https://doi.org/10.1016/B978-0-323-35955-9.00020-9

Risk factors for breast carcinoma in women with proliferative breast disease. / Dupont, William D.; Degnim, Amy C; Sanders, Melinda E.; Simpson, Jean F.; Hartmann, Lynn C.

The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc., 2017. p. 264-271.e2.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dupont, WD, Degnim, AC, Sanders, ME, Simpson, JF & Hartmann, LC 2017, Risk factors for breast carcinoma in women with proliferative breast disease. in The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc., pp. 264-271.e2. https://doi.org/10.1016/B978-0-323-35955-9.00020-9
Dupont WD, Degnim AC, Sanders ME, Simpson JF, Hartmann LC. Risk factors for breast carcinoma in women with proliferative breast disease. In The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc. 2017. p. 264-271.e2 https://doi.org/10.1016/B978-0-323-35955-9.00020-9
Dupont, William D. ; Degnim, Amy C ; Sanders, Melinda E. ; Simpson, Jean F. ; Hartmann, Lynn C. / Risk factors for breast carcinoma in women with proliferative breast disease. The Breast: Comprehensive Management of Benign and Malignant Diseases. Elsevier Inc., 2017. pp. 264-271.e2
@inbook{32b2d0ac785d42009ce8a89a8b13961c,
title = "Risk factors for breast carcinoma in women with proliferative breast disease",
abstract = "We review the evidence that proliferative breast disease increases the risk of breast cancer. Results from six cohorts give consistent estimates of these risks. The combined estimate of the relative risk associated with proliferative disease without atypia is 1.65 with a 95{\%} confidence interval (CI) of 1.5 to 1.9. The relative risk of breast cancer associated with atypical hyperplasia is 4.19 (95{\%} CI 3.7-4.7). Estimates of the cumulative absolute risk of invasive breast cancer in the Nashville Breast Cohort and the Mayo Clinic Cohort are also given. These risks are remarkably consistent and average about 25{\%} in the 25 years after a diagnosis of atypical hyperplasia. The chapter also reviews the evidence on how age, a family history of breast cancer, and proliferative breast disease interact to affect breast cancer risk. The risks associated with fibroadenoma and radial scar are also reviewed, as are the effects of time since diagnosis and the risk of hormone replacement therapy in women with a history of proliferative disease.",
keywords = "Atypical hyperplasia, Breast neoplasms pathology/prevention and control, Breast pathology, Proliferative disease without atypia, Risk assessment",
author = "Dupont, {William D.} and Degnim, {Amy C} and Sanders, {Melinda E.} and Simpson, {Jean F.} and Hartmann, {Lynn C.}",
year = "2017",
month = "8",
day = "24",
doi = "10.1016/B978-0-323-35955-9.00020-9",
language = "English (US)",
isbn = "9780323359559",
pages = "264--271.e2",
booktitle = "The Breast",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Risk factors for breast carcinoma in women with proliferative breast disease

AU - Dupont, William D.

AU - Degnim, Amy C

AU - Sanders, Melinda E.

AU - Simpson, Jean F.

AU - Hartmann, Lynn C.

PY - 2017/8/24

Y1 - 2017/8/24

N2 - We review the evidence that proliferative breast disease increases the risk of breast cancer. Results from six cohorts give consistent estimates of these risks. The combined estimate of the relative risk associated with proliferative disease without atypia is 1.65 with a 95% confidence interval (CI) of 1.5 to 1.9. The relative risk of breast cancer associated with atypical hyperplasia is 4.19 (95% CI 3.7-4.7). Estimates of the cumulative absolute risk of invasive breast cancer in the Nashville Breast Cohort and the Mayo Clinic Cohort are also given. These risks are remarkably consistent and average about 25% in the 25 years after a diagnosis of atypical hyperplasia. The chapter also reviews the evidence on how age, a family history of breast cancer, and proliferative breast disease interact to affect breast cancer risk. The risks associated with fibroadenoma and radial scar are also reviewed, as are the effects of time since diagnosis and the risk of hormone replacement therapy in women with a history of proliferative disease.

AB - We review the evidence that proliferative breast disease increases the risk of breast cancer. Results from six cohorts give consistent estimates of these risks. The combined estimate of the relative risk associated with proliferative disease without atypia is 1.65 with a 95% confidence interval (CI) of 1.5 to 1.9. The relative risk of breast cancer associated with atypical hyperplasia is 4.19 (95% CI 3.7-4.7). Estimates of the cumulative absolute risk of invasive breast cancer in the Nashville Breast Cohort and the Mayo Clinic Cohort are also given. These risks are remarkably consistent and average about 25% in the 25 years after a diagnosis of atypical hyperplasia. The chapter also reviews the evidence on how age, a family history of breast cancer, and proliferative breast disease interact to affect breast cancer risk. The risks associated with fibroadenoma and radial scar are also reviewed, as are the effects of time since diagnosis and the risk of hormone replacement therapy in women with a history of proliferative disease.

KW - Atypical hyperplasia

KW - Breast neoplasms pathology/prevention and control

KW - Breast pathology

KW - Proliferative disease without atypia

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=85054333946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054333946&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-35955-9.00020-9

DO - 10.1016/B978-0-323-35955-9.00020-9

M3 - Chapter

AN - SCOPUS:85054333946

SN - 9780323359559

SP - 264-271.e2

BT - The Breast

PB - Elsevier Inc.

ER -